Human Metabolome Technologies, Inc. Stock price

Equities

6090

JP3794530000

Biotechnology & Medical Research

Market Closed - Japan Exchange 02:00:00 2024-03-28 am EDT 5-day change 1st Jan Change
650 JPY -0.46% Intraday chart for Human Metabolome Technologies, Inc. +2.36% +1.56%
Sales 2022 1.22B 8.08M Sales 2023 1.3B 8.58M Capitalization 4.42B 29.22M
Net income 2022 267M 1.76M Net income 2023 285M 1.88M EV / Sales 2022 2.48 x
Net cash position 2022 1.27B 8.4M Net cash position 2023 1.43B 9.45M EV / Sales 2023 2.31 x
P/E ratio 2022
16.1 x
P/E ratio 2023
15.5 x
Employees -
Yield 2022 *
-
Yield 2023
1.34%
Free-Float 80.56%
More Fundamentals * Assessed data
Dynamic Chart
Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2024 CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024 CI
Human Metabolome Technologies, Inc. Announces Year End Dividend for the Year Ended June 30, 2023, Payable on September 7, 2023; Provides Year End Dividend Guidance for the Year Ending June 30, 2024 CI
Human Metabolome Technologies, Inc. Reports Earnings Results for the Nine Months Ended March 31, 2023 CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending June 2023 CI
Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2023 CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending June 30, 2023 CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023 CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023 CI
Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022 CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022 CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022 CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Fourth Quarter Ended June 2021 CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022 CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Third Quarter Ended March 2021 CI
More news
1 day-0.46%
1 week+2.36%
Current month+3.34%
1 month+3.67%
3 months+5.18%
6 months-11.56%
Current year+1.56%
More quotes
1 week
631.00
Extreme 631
655.00
1 month
627.00
Extreme 627
655.00
Current year
624.00
Extreme 624
678.00
1 year
588.00
Extreme 588
794.00
3 years
545.00
Extreme 545
1 044.00
5 years
453.00
Extreme 453
2 032.00
10 years
453.00
Extreme 453
2 890.00
More quotes
Managers TitleAgeSince
President 55 18-02-28
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 58 20-06-30
Corporate Officer/Principal 49 05-06-30
Director/Board Member 80 17-06-23
More insiders
Date Price Change Volume
24-03-28 650 -0.46% 4 000
24-03-27 653 +1.56% 6,100
24-03-26 643 +0.16% 8,700
24-03-25 642 +0.78% 8,500
24-03-22 637 +0.31% 3,700

Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT

More quotes
Human Metabolome Technologies, Inc. is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions. The Company operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.
More about the company
  1. Stock
  2. Equities
  3. Stock Human Metabolome Technologies, Inc. - Japan Exchange